Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

GlaxoSmithKline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,728.90
  • Today's Change48.90 / 1.82%
  • Shares traded6.62k
  • 1 Year change+91.64%
  • Beta0.4361
Data delayed at least 15 minutes, as of Nov 01 2024 13:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.

  • Revenue in INR (TTM)35.60bn
  • Net income in INR6.75bn
  • Incorporated1924
  • Employees3.21k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pfizer Ltd22.38bn6.18bn233.22bn1.72k37.756.2234.3610.42135.06135.06489.19819.900.52881.8311.1613,004,360.0014.6014.2217.0517.7165.0061.3727.6124.054.3046.210.026782.67-9.551.05-11.645.1433.359.24
Natco Pharma Ltd.42.21bn16.37bn251.28bn4.02k15.35--13.785.9591.3791.37235.68--------10,510,210.00--12.33--14.2583.4073.0538.7725.16--91.13--18.9647.7213.8194.0916.59-4.7114.87
Laurus Labs Ltd50.53bn1.31bn264.86bn6.01k201.926.4048.585.242.432.4393.7076.700.6021.183.068,412,186.001.5510.132.5216.4753.4447.632.5812.830.58181.810.402313.00-16.5517.07-79.6811.3621.6821.67
Gland Pharma Ltd58.58bn7.22bn272.02bn4.22k37.67--24.884.6443.8343.83355.57--------13,890,770.00--13.23--14.5661.0055.5812.3322.92--34.66--7.2656.2922.61-1.1011.3224.02--
Emcure Pharmaceuticals Ltd-100.00bn-100.00bn272.13bn11.15k--------------------------7.14--13.93--59.29--7.81------0.0011.237.14-6.3621.35-5.93--
J B Chemicals and Pharmaceuticals Ltd35.92bn5.87bn304.58bn5.31k53.02--41.458.4836.9936.99226.16--------6,764,044.00--15.77--18.8966.2761.1816.3416.06--21.04--33.0810.6316.2234.8423.3640.1537.42
Suven Pharmaceuticals Ltd9.34bn2.40bn334.35bn1.05k138.89--112.9935.789.469.4636.75--------8,883,019.00--23.17--26.2056.5958.8525.7333.21--33.74--18.63-21.5622.71-26.9922.41-1.83--
Piramal Pharma Ltd87.04bn453.30m354.33bn6.72k787.954.4844.044.070.34070.340766.3659.910.57991.404.8812,954,040.000.302--0.428--63.69--0.5208--0.56037.490.3771--15.39--109.56------
Ajanta Pharma Ltd44.91bn8.75bn382.82bn7.84k44.0610.4137.838.5269.5569.55356.94294.360.97381.334.165,725,128.0018.9716.6123.2920.4775.7773.2219.4819.312.1349.880.008831.2012.4515.4138.8116.10-14.9710.76
IPCA Laboratories Ltd82.12bn5.77bn403.09bn17.34k69.88--42.484.9122.7422.74323.71--------4,737,502.00--10.33--13.5267.0859.166.8412.25--15.41--12.8623.3915.3516.134.2417.9021.67
GlaxoSmithKline Pharmaceuticals Limited35.60bn6.75bn459.47bn3.21k68.4927.4761.8012.9039.6039.60209.3198.741.012.5914.8511,088,370.0019.2411.0136.0917.8861.7055.7718.9612.251.38554.800.0088192.076.212.00-2.915.78-36.029.86
Glenmark Pharmaceuticals Ltd120.21bn-15.73bn478.18bn14.99k------3.98-55.78-46.50425.96--------8,020,026.00--1.02--1.4363.9359.47-12.711.43--1.78--56.981.983.67-1,018.93---5.894.56
Abbott India Ltd59.28bn12.39bn615.78bn3.81k49.70--46.9610.39583.08583.082,789.54--------15,541,480.00--20.92--28.5945.2844.2020.9017.26--119.46--77.069.359.7226.5221.6831.0852.32
Data as of Nov 01 2024. Currency figures normalised to GlaxoSmithKline Pharmaceuticals Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

9.16%Per cent of shares held by top holders
HolderShares% Held
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 20235.68m3.36%
The Vanguard Group, Inc.as of 02 Oct 20241.56m0.92%
Kotak Mahindra Asset Management Co. Ltd.as of 30 Sep 20241.55m0.92%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Sep 20241.44m0.85%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 20241.43m0.85%
General Insurance Corp. of India (Invt Port)as of 31 Mar 20241.17m0.69%
quant Money Managers Ltd.as of 30 Sep 20241.16m0.68%
BlackRock Fund Advisorsas of 03 Oct 2024613.52k0.36%
Dimensional Fund Advisors LPas of 03 Oct 2024465.52k0.28%
Norges Bank Investment Managementas of 30 Jun 2024454.51k0.27%
More ▼
Data from 30 Jun 2024 - 24 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.